Company: SINT
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021930
Chunk: 33

Company: Sintx Technologies, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 33
---
 in the reports filed
or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Commission’s
rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be
disclosed in our reports filed or submitted under the Exchange Act are properly recorded, processed, summarized and reported within the
time periods required by the Commission’s rules and forms.

We
carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer
(Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer), of the effectiveness of the design
and operation of these disclosure controls and procedures, as such term is defined in Exchange Act Rule 13a-15(e), as of September 30,
2025. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective as of September 30, 2025, the end of the period covered by this Quarterly Report on Form 10-Q.

Changes
in Internal Control over Financial Reporting

There
were no changes in our internal control over financial reporting that occurred during the third quarter of 2025 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23

PART
II

ITEM
1. LEGAL PROCEEDINGS

We
are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating
results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding
patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various legal
proceedings from time to time.

Item
1A. Risk Factors

Information
regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with
the SEC on March 19, 2025. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form
10-K.

ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Share
Repurchase Program

In
November 2024, the Company announced that its board of directors authorized a share repurchase program that would allow the Company
to repurchase up to $500,000